Phenex is a world-renowned drug discovery and development company focused on the target class of nuclear receptors for the development of novel pharmaceuticals.
Location: Germany, Baden-Württemberg, Heidelberg
Total raised: $7.91M
Investors 1
| Date | Name | Website |
| - | Creathor V... | creathor.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.09.2010 | Series C | $7.91M | - |
Mentions in press and media 6
| Date | Title | Description |
| 21.04.2017 | Gilead’s billion-dollar NASH acquisition takes some positive first steps | It’s an early win for a drug Gilead acquired from Nimbus Therapeutics in April 2016. A handful of other preclinical programs were included in the deal, which saw Gilead pay an upfront $400 million. A further $200 million was paid out last N... |
| 05.01.2017 | Gilead tosses $100M milestone chip in its fast-growing gamble on new NASH drugs | Almost two years to the day since Gilead $GILD struck a deal worth up to $470 million for Phenex’s FXR agonist program for NASH, the big biotech has followed up with a $100 million milestone payment. Phenex execs say that Gilead h... |
| 21.09.2010 | Phenex Raises €6M in Series C Financing | Phenex Pharmaceuticals AG, a Ludwigshafen, Germany-based drug discovery and development company, closed a €6m Series C financing round (approximately $7,8m). This brings the total amount raised by the company through three rounds of funding... |
| - | Phenex receives $100 million milestone payment from Gilead | Ludwigshafen, Germany, January 06, 2017 – Phenex Pharmaceuticals AG (Phenex) yesterday announced that the company has received a 100 M USD milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A., for its program with GS-9674... |
| - | Gilead’s billion-dollar NASH acquisition takes some positive first steps | While a Phase 2 trial powers on, Gilead Sciences has announced some earlier proof-of-concept data for its investigational acetyl-CoA carboxylase (ACC) inhibitor, GS-0976, in patients with non-alcoholic steatohepatitis (NASH). The results we... |
| - | Phenex announces milestone payment from Janssen | Phenex drug discovery has now resulted in two clinical stage programs this year through research collaborations |